Drugs / TGN-1412
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03006029 | Feb 2017 → May 2019 | cancer | Theramab LLC | Completed | No outcome recorded |
| Phase 1 | NCT01885624 | Nov 2011 → May 2013 | — | Theramab LLC | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT02796053 | Apr → Dec 2016 | psoriasis | Theramab LLC | Completed | No outcome recorded |
| Phase 1/2 | NCT01990157 | Nov 2013 → Dec 2015 | rheumatoid arthritis | Theramab LLC | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02711813 | Mar 2016 → May 2018 | systemic lupus erythematosus | Theramab LLC | Terminated | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TGN-1412 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109250 ↗ |
| Known as | CD28-SUPERMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109250 ↗ |
| Known as | TAB08 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02796053 ↗ |
| Known as | Theralizumab | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109250 ↗ |
| Action | Activate | “T-cell-specific surface glycoprotein CD28 agonist” CHEMBL2109250 ↗ |
| Modality | Monoclonal antibody | “monoclonal antibody” NCT01885624 ↗ |
| Route | Intravenous | “after single i.v. infusion” NCT01885624 ↗ |
| Target | CD28 | “T-cell-specific surface glycoprotein CD28 agonist” CHEMBL2109250 ↗ |